FIGURE 1

Analysis of 4-hour Postprandial Plasma Glucose Concentrations Following Breakfast (Day 1 to Day 14)

Time point	Placebo (N = 11)	25 mg (N = 15)	100 mg (N = 14)	400 mg (N = 15)	All Active (N = 45)
Day -1					
n	11	15	14	15	44
Mean (SD)	230.7 (68.57)	235.7 (83.67)	210.6 (52.07)	254.3 (69.57)	234.1 (70.70)
Min, Max	133.6, 357.5	137.2, 371.6	138.6, 301.5	157.5, 385.7	137.2, 385.7
Day 14 Actual					
n	11	15	14	13	42
Mean (SD)	238.9 (81.95)	203.2 (82.61)	173.5 (44.32)	198.6 (58.30)	191.8 (64.22)
Min, Max	149.7, 351.5	100.6, 368.6	115.5, 251.7	131.8, 340.7	100.6, 368.6
Day 14 Change from Baseline					
n	11	15	14	13	42
Mean (SD)	8.2 (49.20)	-32.5 (22.26)	-37.2 (36.55)	-65.6 (41.85)	-44.3 (36.30)
Min, Max	-65.0, 83.6	-72.7, 11.2	-120.3, 19.5	-172.7, -12.3	-172.7, 19.5
Difference in Change from Baseline from Placebo					
LS Mean (SE)	–	-39.9 (14.42)	-48.6 (14.71)	-68.3 (15.08)	-52.3 (12.31)
P value[1]	–	0.008	0.002	<0.001	
P value[2]					<0.001

Note: Units are mg/dL

LS Mean = Least squares mean from ANCOVA with Day -1 value as a covariate. The model includes effects for treatment, the baseline covariate, and interaction between treatment and baseline covariate.

[1] *P* values are from ANCOVA model, active dose vs placebo contrast, with no multiple comparisons adjustment.

[2] *P* values are from ANCOVA model, all active vs placebo contrast

FIGURE 2

Analysis of Glycosylated Hemoglobin (HbA_{1c})

Time point	Placebo (N = 11)	25 mg (N = 15)	100 mg (N = 14)	400 mg (N = 16)	All Active (N = 45)
Day -7					
n	11	15	14	15	44
Mean (SD)	7.74 (0.692)	7.87 (1.750)	7.65 (1.208)	8.01 (1.398)	7.85 (1.448)
Min, Max	6.6, 8.7	6.3, 11.1	6.5, 10.0	6.7, 10.9	6.3, 11.1
Day 15 Actual					
n	11	14	14	13	41
Mean (SD)	7.79 (0.991)	7.76 (1.728)	7.25 (1.145)	7.82 (1.438)	7.60 (1.444)
Min, Max	5.9, 9.1	6.1, 11.1	5.6, 9.8	6.5, 10.9	5.6, 11.1
Day 15 Change from Baseline					
n	11	14	14	13	41
Mean (SD)	0.05 (0.364)	-0.22 (0.316)	-0.40 (0.302)	-0.28 (0.292)	-0.30 (0.306)
Min, Max	-0.8, 0.4	-1.0, 0.4	-1.0, 0.0	-0.8, 0.1	-1.0, 0.4
Difference in Change from Baseline from Placebo					
LS Mean (SE)	–	-0.27 (0.129)	-0.45 (0.128)	-0.32 (0.131)	-0.35 (0.108)
P value[1]	–	0.044	<0.001	0.018	
P value[2]					0.002

Note: Units are %

LS Mean = Least squares mean from ANCOVA with Day -7 value as a covariate. The model includes effects for treatment, the baseline covariate, and interaction between treatment and baseline covariate.

[1] *P* values are from ANCOVA model, active dose vs placebo contrast, with no multiple comparisons adjustment.

[2] *P* values are from ANCOVA model, all active vs placebo contrast

FIGURE 3

Analysis of Fasting Fructosamine

Time point	Placebo (N = 11)	25 mg (N = 15)	100 mg (N = 14)	400 mg (N = 16)	All Active (N = 45)
Day -7					
n	11	15	14	15	44
Mean (SD)	313.8 (49.47)	300.1 (73.58)	289.6 (47.37)	324.9 (73.90)	305.2 (66.66)
Min, Max	247, 392	207, 420	212, 360	225, 463	207, 463
Day 15 Actual					
n	11	14	14	13	41
Mean (SD)	328.8 (68.27)	310.7 (76.04)	263.9 (42.05)	312.6 (68.13)	295.3 (66.12)
Min, Max	239, 459	208, 443	165, 351	233, 481	165, 481
Day 15 Change from Baseline					
n	11	14	14	13	41
Mean (SD)	15.0 (22.78)	6.3 (39.42)	-25.6 (28.35)	-19.9 (26.38)	-12.9 (34.29)
Min, Max	-10, 67	-76, 79	-83, 9	-74, 18	-83, 79
Difference in Change from Baseline from Placebo					
LS Mean (SE)	–	-9.6 (12.15)	-42.9 (12.24)	-33.2 (12.40)	-28.6 (10.23)
P value[1]	–	0.433	0.001	0.010	
P value[2]					0.008

Note: Units are micromoles/L

LS Mean = Least squares mean from ANCOVA with Day -7 value as a covariate. The model includes effects for treatment, the baseline covariate, and interaction between treatment and baseline covariate.

[1] *P* values are from ANCOVA model, active dose vs placebo contrast, with no multiple comparisons adjustment.

[2] *P* values are from ANCOVA model, all active vs placebo contrast

FIGURE 4

DPP IV inhibition after daily single oral administration of
Compound I for 14 days in a newly-diagnosed type II diabetes patient population

